← All trials
NCT05431257
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 24, 2022
- Primary completion
- Sep 1, 2031
- Completion date
- Sep 1, 2031
- First posted
- Jun 24, 2022
- Last posted
- Jun 24, 2022
- Enrollment
- 117
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of CopenhagenLead sponsor
- Helse Møre og Romsdal HFCollaborator
- Lund UniversityCollaborator
- Norwegian University of Science and TechnologyCollaborator
- University Hospital of North NorwayCollaborator
- University of OuluCollaborator
- University of TampereCollaborator
- University of BergenCollaborator
- University of CopenhagenReponsible party - principal investigator
- Uppsala UniversityCollaborator
- Karolinska InstituteCollaborator
- Kuopio University HospitalCollaborator
- Vestre Viken Ringerike SykehusCollaborator
- University of StavangerCollaborator
- University of HelsinkiCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.